Synopsis
Synopsis
0
EU WC
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Neomycin
2. Neomycin Palmitate
3. Neomycin Sulfate
1. Neomycin Sulfate
2. 1405-10-3
3. Neomycin Trisulfate Hydrate
4. Akos016010116
Molecular Weight | 712.7 g/mol |
---|---|
Molecular Formula | C23H48N6O17S |
Hydrogen Bond Donor Count | 15 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 9 |
Exact Mass | 712.27966526 g/mol |
Monoisotopic Mass | 712.27966526 g/mol |
Topological Polar Surface Area | 436 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 953 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
2 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13615
Submission : 1998-09-01
Status : Inactive
Type : II
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-26
Pay. Date : 2013-02-13
DMF Number : 13378
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1999-184 - Rev 03
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Status : Valid
Registration Number : 217MF10976
Registrant's Address : 235 East 42nd Street, New York, NY 10017
Initial Date of Registration : 2005-11-14
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32091
Submission : 2017-09-08
Status : Active
Type : II
Certificate Number : R1-CEP 2011-029 - Rev 01
Issue Date : 2020-02-27
Type : Chemical and TSE
Substance Number : 197
Status : Valid
Registration Number : 303MF10156
Registrant's Address : No. 8,Ziyang Road,Dianjun District,Yichang City,HubeiProvince,China
Initial Date of Registration : 2021-10-07
Latest Date of Registration :
NDC Package Code : 65876-0005
Start Marketing Date : 2018-05-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6443
Submission : 2021-10-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 124
Submission : 1953-07-23
Status : Inactive
Type : II
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Novartis Korea Ltd.
Registration Date : 2023-08-01
Registration Number : 20230801-211-J-1531
Manufacturer Name : Pharmacia & Upjohn Company LLC
Manufacturer Address : 7000 Portage Road, Kalamazoo, Michigan 49001, USA
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 262
Submission : 1940-01-01
Status : Inactive
Type : II
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 110
Submission : 1953-05-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 264
Submission : 1957-07-26
Status : Inactive
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13615
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-26
Pay. Date : 2013-02-13
DMF Number : 13378
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 271
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 270
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 262
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 124
Submission : 1953-07-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13286
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 264
Submission : 1957-07-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 110
Submission : 1953-05-29
Status : Inactive
Type : II
Neomycin Sulfate, Micronised And Non-micronised
Certificate Number : R1-CEP 1999-184 - Rev 03
Status : Valid
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Certificate Number : R1-CEP 2017-006 - Rev 00
Status : Valid
Issue Date : 2023-04-13
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2001-317 - Rev 00
Status : Valid
Issue Date : 2010-09-07
Type : Chemical
Substance Number : 197
Certificate Number : R0-CEP 2022-013 - Rev 01
Status : Valid
Issue Date : 2023-02-15
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2011-029 - Rev 01
Status : Valid
Issue Date : 2020-02-27
Type : Chemical and TSE
Substance Number : 197
Registration Number : 217MF10976
Registrant's Address : 235 East 42nd Street, New York, NY 10017
Initial Date of Registration : 2005-11-14
Latest Date of Registration : 2022-06-22
Registration Number : 303MF10156
Registrant's Address : No. 8,Ziyang Road,Dianjun District,Yichang City,HubeiProvince,China
Initial Date of Registration : 2021-10-07
Latest Date of Registration : 2021-10-07
Registrant Name : Novartis Korea Ltd.
Registration Date : 2023-08-01
Registration Number : 20230801-211-J-1531
Manufacturer Name : Pharmacia & Upjohn Company L...
Manufacturer Address : 7000 Portage Road, Kalamazoo, Michigan 49001, USA
NDC Package Code : 51551-0307
Start Marketing Date : 2005-07-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66405-0005
Start Marketing Date : 2017-12-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 55718-145
Start Marketing Date : 1995-10-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 55718-163
Start Marketing Date : 1994-07-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 65876-0004
Start Marketing Date : 2017-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1[BAU]/[BAU])
Marketing Category : BULK INGREDIENT
NDC Package Code : 43457-538
Start Marketing Date : 2022-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 65876-0001
Start Marketing Date : 2018-03-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 55718-162
Start Marketing Date : 1996-10-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Lead Product(s): Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Maxitrol-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 24, 2025
Lead Product(s) : Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Harrow
Deal Size : Undisclosed
Deal Type : Partnership
Nordic Pharma Launches Authorized Generic of Maxitrol in the U.S.
Details : The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Product Name : Maxitrol-Generic
Product Type : Steroid
Upfront Cash : Undisclosed
April 24, 2025
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
22
PharmaCompass offers a list of Neomycin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Neomycin Sulfate manufacturer or Neomycin Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neomycin Sulfate manufacturer or Neomycin Sulfate supplier.
PharmaCompass also assists you with knowing the Neomycin Sulfate API Price utilized in the formulation of products. Neomycin Sulfate API Price is not always fixed or binding as the Neomycin Sulfate Price is obtained through a variety of data sources. The Neomycin Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fradiomycin Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fradiomycin Sulfate, including repackagers and relabelers. The FDA regulates Fradiomycin Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fradiomycin Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fradiomycin Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fradiomycin Sulfate supplier is an individual or a company that provides Fradiomycin Sulfate active pharmaceutical ingredient (API) or Fradiomycin Sulfate finished formulations upon request. The Fradiomycin Sulfate suppliers may include Fradiomycin Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Fradiomycin Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fradiomycin Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Fradiomycin Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Fradiomycin Sulfate DMFs exist exist since differing nations have different regulations, such as Fradiomycin Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fradiomycin Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Fradiomycin Sulfate USDMF includes data on Fradiomycin Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fradiomycin Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fradiomycin Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fradiomycin Sulfate Drug Master File in Japan (Fradiomycin Sulfate JDMF) empowers Fradiomycin Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fradiomycin Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Fradiomycin Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fradiomycin Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fradiomycin Sulfate Drug Master File in Korea (Fradiomycin Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fradiomycin Sulfate. The MFDS reviews the Fradiomycin Sulfate KDMF as part of the drug registration process and uses the information provided in the Fradiomycin Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fradiomycin Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fradiomycin Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fradiomycin Sulfate suppliers with KDMF on PharmaCompass.
A Fradiomycin Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Fradiomycin Sulfate Certificate of Suitability (COS). The purpose of a Fradiomycin Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Fradiomycin Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Fradiomycin Sulfate to their clients by showing that a Fradiomycin Sulfate CEP has been issued for it. The manufacturer submits a Fradiomycin Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Fradiomycin Sulfate CEP holder for the record. Additionally, the data presented in the Fradiomycin Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Fradiomycin Sulfate DMF.
A Fradiomycin Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Fradiomycin Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Fradiomycin Sulfate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fradiomycin Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fradiomycin Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fradiomycin Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fradiomycin Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fradiomycin Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fradiomycin Sulfate suppliers with NDC on PharmaCompass.
Fradiomycin Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fradiomycin Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fradiomycin Sulfate GMP manufacturer or Fradiomycin Sulfate GMP API supplier for your needs.
A Fradiomycin Sulfate CoA (Certificate of Analysis) is a formal document that attests to Fradiomycin Sulfate's compliance with Fradiomycin Sulfate specifications and serves as a tool for batch-level quality control.
Fradiomycin Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Fradiomycin Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fradiomycin Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Fradiomycin Sulfate EP), Fradiomycin Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fradiomycin Sulfate USP).